Yi Li

Prof. Yi Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in NeuroImage
Verified
Journal Article
Closed access
DHDonald J. Hagler
Donald J. Hagler
SHSeanN. Hatton
SeanN. Hatton
MCM. Daniela Cornejo
M. Daniela Cornejo
CMCarolina Makowski
Carolina Makowski
DFDamien A. Fair
Damien A. Fair
ADAnders M. Dale
Anders M. Dale

14 January 2009 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LMLisa Mosconi
Lisa Mosconi
RMRachel Mistur
Rachel Mistur
RSRemigiusz Switalski
Remigiusz Switalski
WTWai Hon Tsui
Wai Hon Tsui
LGLidia Glodzik
Lidia Glodzik
MLMony J. de Leon
Mony J. de Leon

1 May 2008 in Neurobiology of Aging
Verified
Journal Article
Closed access
LMLisa Mosconi
Lisa Mosconi
SSSusan De Santi
Susan De Santi
JLJuan Li
Juan Li
WTWai Hon Tsui
Wai Hon Tsui
YLYi Li
Yi Li
MLMony J. de Leon
Mony J. de Leon

14 June 2005 in Neurology
Verified
Journal Article
Closed access
LML. Mosconi
L. Mosconi
WTW. -H. Tsui
W. -H. Tsui
SSS. De Santi
S. De Santi
JLJ. Li
J. Li
HRH. Rusinek
H. Rusinek
MLM. J. de Leon
M. J. de Leon
To facilitate image analysis, most recent 2-[18F]fluoro-2-deoxy-d-glucose PET (FDG-PET) studies of glucose metabolism (MRglc) have used automated voxel-based analysis (VBA) procedures but paradoxically none reports hippocampus MRglc reductions in mild cognitive impairment (MCI) or Alzheimer disease (AD). Only a few studies, those using regions of interest (ROIs), report hippocampal reductions. The authors created an automated and anatomically valid mask technique to sample the hippocampus on PET (HipMask). Hippocampal ROIs drawn on the MRI of 48 subjects (20 healthy elderly [NL], 16 MCI, and 12 AD) were used to develop the HipMask. The HipMask technique was applied in an FDG-PET study of NL (n = 11), MCI (n = 13), and AD (n = 12), and compared to both MRI-guided ROIs and VBA methods. HipMask and ROI hippocampal sampling produced significant and equivalent MRglc reductions for contrasts between MCI and AD relative to NL. The VBA showed typical cortical effects but failed to show hippocampal MRglc reductions in either clinical group. Hippocampal MRglc was the only discriminator of NL vs MCI (78% accuracy) and added to the cortical MRglc in classifying NL vs AD and MCI vs AD. The new HipMask technique provides accurate and rapid assessment of the hippocampus on PET without the use of regions of interest. Hippocampal glucose metabolism reductions are found in both mild cognitive impairment and Alzheimer disease and contribute to their diagnostic classification. These results suggest re-examination of prior voxel-based analysis 2-[18F]fluoro-2-deoxy-d-glucose PET studies that failed to report hippocampal effects.

27 October 2017 in The World Journal of Biological Psychiatry
Verified
Journal Article
Open access
PLPiotr Lewczuk
Piotr Lewczuk
RPRiederer Peter
Riederer Peter
OEO'Bryant Sid E
O'Bryant Sid E
VMVerbeek Marcel M
Verbeek Marcel M
DBDubois Bruno
Dubois Bruno
JKJohannes Konrhuber
Johannes Konrhuber
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

16 March 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MLMony J. de Leon
Mony J. de Leon
YLYi Li
Yi Li
NONobuyuki Okamura
Nobuyuki Okamura
WTWai H. Tsui
Wai H. Tsui
LSLes A. Saint-Louis
Les A. Saint-Louis
HRHenry Rusinek
Henry Rusinek
Evidence supporting the hypothesis that reduced cerebrospinal fluid (CSF) clearance is involved in the pathophysiology of Alzheimer disease (AD) comes primarily from rodent models. However, unlike rodents, in which predominant extracranial CSF egress is via olfactory nerves traversing the cribriform plate, human CSF clearance pathways are not well characterized. Dynamic PET with 18F‐THK5117, a tracer for tau pathology, was used to estimate the ventricular CSF time–activity as a biomarker for CSF clearance. We tested 3 hypotheses: extracranial CSF is detected at the superior turbinates; CSF clearance is reduced in AD; and CSF clearance is inversely associated with amyloid deposition. Methods: Fifteen subjects, 8 with AD and 7 normal control volunteers, were examined with 18F‐THK5117. Ten subjects additionally underwent 11C-Pittsburgh compound B (11C-PiB) PET scanning, and 8 were 11C-PiB–positive. Ventricular time–activity curves of 18F‐THK5117 were used to identify highly correlated time–activity curves from extracranial voxels. Results: For all subjects, the greatest density of CSF-positive extracranial voxels was in the nasal turbinates. Tracer concentration analyses validated the superior nasal turbinate CSF signal intensity. AD patients showed ventricular tracer clearance reduced by 23% and 66% fewer superior turbinate CSF egress sites. Ventricular CSF clearance was inversely associated with amyloid deposition. Conclusion: The human nasal turbinate is part of the CSF clearance system. Lateral ventricle and superior nasal turbinate CSF clearance abnormalities are found in AD. Ventricular CSF clearance reductions are associated with increased brain amyloid depositions. These data suggest that PET-measured CSF clearance is a biomarker of potential interest in AD and other neurodegenerative diseases.